Please use this identifier to cite or link to this item:
http://hdl.handle.net/10603/471029
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.coverage.spatial | To identify small molecule inhibitors for cancer targets C J UN N Terminal Kinase 1 JNK 1 and estrogen receptor a ER a using in silico spectroscopic and in vitro studies | |
dc.date.accessioned | 2023-03-20T10:12:57Z | - |
dc.date.available | 2023-03-20T10:12:57Z | - |
dc.identifier.uri | http://hdl.handle.net/10603/471029 | - |
dc.description.abstract | The disease cancer is a threat to humanity. It is found that globally, newlineone in five men and one in six women will develop the disease in their lifespan. newlineAlso, one in eight men and one in twelve women die because of the disease newline(Nelson Roxanne 2020). Cancer death is the second major cause of death newlineworldwide. Also, it is the second reason for the loss of the economy worldwide newlinesince a huge amount of money around $1.16 trillion is spent globally for newlinetreatment and identification of drugs, but in vain (Stewart BW Wild 2014). newlineAlso, statistics from WHO says that the death rate will further increase in the newlineupcoming years, because of the increase in population and life style newline(Bray F Ferlay 2018). In addition to the pain caused by disease the patient newlinealso undergoes more painful treatment procedures for an extended period. newlineThus researchers from various fields work together to improve the quality of newlinelife of cancer patients by easing the screening process, identifying painless newlinetargeted therapy with no side-effect, and thus increasing the survival rate. newlineGlobally the pharmaceutical companies are investing a huge sum of money to newlineidentify potent drugs for various types of cancer in a lesser time frame newline(Wouters OJ 2020). Thus the need for providing a quality life for cancer newlinepatients motivated us to design drugs for potent cancer targets. newlineDrug designing is a lengthy, time-consuming process and evolves newlinewith the advancement in various fields involved in designing. The thesis newlinepresented consists of five chapters. Chapter 1 provides an overview of the newlinedrug and highlights the advancement in major fields involved in the drug newlinedesign process viz. CADD, HTVS, chem-informatics, bioinformatics, and newlinecombinatorial chemistry. newline | |
dc.format.extent | xxv,147p. | |
dc.language | English | |
dc.relation | p.132-146 | |
dc.rights | university | |
dc.title | To identify small molecule inhibitors for cancer targets C J UN N Terminal Kinase 1 JNK 1 and estrogen receptor a ER a using in silico spectroscopic and in vitro studies | |
dc.title.alternative | ||
dc.creator.researcher | Shylaja, R | |
dc.subject.keyword | Engineering | |
dc.subject.keyword | Engineering and Technology | |
dc.subject.keyword | Engineering Biomedical | |
dc.description.note | ||
dc.contributor.guide | Meganathan, C | |
dc.publisher.place | Chennai | |
dc.publisher.university | Anna University | |
dc.publisher.institution | Faculty of Science and Humanities | |
dc.date.registered | ||
dc.date.completed | 2022 | |
dc.date.awarded | 2022 | |
dc.format.dimensions | 21cm | |
dc.format.accompanyingmaterial | None | |
dc.source.university | University | |
dc.type.degree | Ph.D. | |
Appears in Departments: | Faculty of Science and Humanities |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
01_title.pdf | Attached File | 257.19 kB | Adobe PDF | View/Open |
02_prelim pages.pdf | 6.84 MB | Adobe PDF | View/Open | |
03_content.pdf | 495.26 kB | Adobe PDF | View/Open | |
04_abstract.pdf | 429.38 kB | Adobe PDF | View/Open | |
05_chapter 1.pdf | 4.72 MB | Adobe PDF | View/Open | |
06_chapter 2.pdf | 6.87 MB | Adobe PDF | View/Open | |
07_chapter 3.pdf | 10.93 MB | Adobe PDF | View/Open | |
08_chapter 4.pdf | 11.81 MB | Adobe PDF | View/Open | |
09_annexures.pdf | 7.18 MB | Adobe PDF | View/Open | |
80_recommendation.pdf | 2.03 MB | Adobe PDF | View/Open |
Items in Shodhganga are licensed under Creative Commons Licence Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0).
Altmetric Badge: